Literature DB >> 32397231

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines.

Giulia Anderluzzi1,2, Gustavo Lou1,2, Simona Gallorini2, Michela Brazzoli2, Russell Johnson3, Derek T O'Hagan3, Barbara C Baudner2, Yvonne Perrie1.   

Abstract

messenger RNA (mRNA)-based vaccines combine the positive attributes of both live-attenuated and subunit vaccines. In order for these to be applied for clinical use, they require to be formulated with delivery systems. However, there are limited in vivo studies which compare different delivery platforms. Therefore, we have compared four different cationic platforms: (1) liposomes, (2) solid lipid nanoparticles (SLNs), (3) polymeric nanoparticles (NPs) and (4) emulsions, to deliver a self-amplifying mRNA (SAM) vaccine. All formulations contained either the non-ionizable cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium bromide (DDA) and they were characterized in terms of physico-chemical attributes, in vitro transfection efficiency and in vivo vaccine potency. Our results showed that SAM encapsulating DOTAP polymeric nanoparticles, DOTAP liposomes and DDA liposomes induced the highest antigen expression in vitro and, from these, DOTAP polymeric nanoparticles were the most potent in triggering humoral and cellular immunity among candidates in vivo.

Entities:  

Keywords:  antigen expression; emulsions; immunogenicity; liposomes; polymeric nanoparticles; self-amplifying RNA; solid lipid nanoparticles

Year:  2020        PMID: 32397231     DOI: 10.3390/vaccines8020212

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  7 in total

Review 1.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 2.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 3.  An Update on Self-Amplifying mRNA Vaccine Development.

Authors:  Anna K Blakney; Shell Ip; Andrew J Geall
Journal:  Vaccines (Basel)       Date:  2021-01-28

Review 4.  Perspectives on RNA Vaccine Candidates for COVID-19.

Authors:  Pobitra Borah; Pran Kishore Deb; Nizar A Al-Shar'i; Lina A Dahabiyeh; Katharigatta N Venugopala; Vinayak Singh; Pottathil Shinu; Snawar Hussain; Satyendra Deka; Balakumar Chandrasekaran; Da'san M M Jaradat
Journal:  Front Mol Biosci       Date:  2021-03-25

5.  The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.

Authors:  Giulia Anderluzzi; Gustavo Lou; Stuart Woods; Signe Tandrup Schmidt; Simona Gallorini; Michela Brazzoli; Russell Johnson; Craig W Roberts; Derek T O'Hagan; Barbara C Baudner; Yvonne Perrie
Journal:  J Control Release       Date:  2021-12-10       Impact factor: 9.776

Review 6.  Clinical progress of nanomedicine-based RNA therapies.

Authors:  Siyoung A Lim; Alysia Cox; Madelynn Tung; Eun Ji Chung
Journal:  Bioact Mater       Date:  2021-10-22

7.  Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics.

Authors:  Carla B Roces; Gustavo Lou; Nikita Jain; Suraj Abraham; Anitha Thomas; Gavin W Halbert; Yvonne Perrie
Journal:  Pharmaceutics       Date:  2020-11-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.